Cardiovascular Risk Reduction With Liraglutide: An Exploratory Mediation Analysis of the LEADER Trial

2020163 citationsJournal Articlegreen Open Access

Authors

John B. Buse · University of North Carolina at Chapel Hill

Stephen C. Bain · Swansea University

Johannes F.E. Mann · Friedrich-Alexander-Universität Erlangen-Nürnberg

Michael A. Nauck · St. Josef-Hospital

Steven E. Nissen · Cleveland Clinic

Stuart Pocock · University of London

Neil R Poulter

Abstract

These analyses identify HbA<sub>1c</sub> and, to a lesser extent, UACR as potential mediators of the CV effects of liraglutide. Whether either is a marker of an unmeasured factor or a true mediator remains a key question that invites further investigation.

Topics & Keywords

Diabetes Treatment and Management Metabolism, Diabetes, and Cancer Hyperglycemia and glycemic control in critically ill and hospitalized patients

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: Diabetes Care

Volume 43, Issue 7, pp. 1546-1552

DOI: 10.2337/dc19-2251

Field-Weighted Citation Impact: 12.49